| Literature DB >> 27115042 |
Paolo Bossi1, Diego Cortinovis2, Maria Cossu Rocca3, Fausto Roila4, Patrizia Seminara5, Alessandra Fabi6, Stefania Canova2, Elena Verri3, Sonia Fatigoni4, Alessandro Iannace5, Fabio Macchi7, Carla Ripamonti1.
Abstract
Patients with cancer frequently use dietary supplementation and herbal therapies to control symptoms of disease and adverse effects of cancer therapy. Despite the widespread use of dietary supplementation and herbal therapies in oncology, robust scientific evidence in this area is lacking. Not only do these products need to be tested in large and well-designed observational or randomized studies, but their manufacturing process must be improved to achieve higher levels of standardization in product quality. Ginger is frequently used to counteract chemotherapy-induced nausea and vomiting (CINV), and some suggestions that it might be effective against CINV come from randomized and/or crossover clinical trials. However, several limitations in the methods of these studies limit their power and generalizability. The authors are conducting a randomized, double-blind study with a large sample size and homogeneous inclusion criteria in order to evaluate the efficacy of a well-standardized ginger extract in reducing nausea in patients with cancer. The widespread use of standardized herbal therapies and natural components among patients requires that scientific and rigorous research strategies are applied in this field to guide the physicians and the patients in safer use.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27115042 PMCID: PMC4921900 DOI: 10.1089/acm.2015.0315
Source DB: PubMed Journal: J Altern Complement Med ISSN: 1075-5535 Impact factor: 2.579